Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  New England Journal of Medicine

• Publication date

  1986-09-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM198609113151102PMID 2427948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.

  1985cited by this paper
• Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

  1985cited by this paper
• A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth.

  1985cited by this paper
• Rapid reversal of carcinoid crisis with a somatostatin analogue.

  1985cited by this paper
• Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport.

  1985cited by this paper
• Somatostatin (First of two parts)

  1983cited by this paper
• Treatment of the carcinoid tumor and the malignant carcinoid syndrome.

  1983cited by this paper
• Somatostatin.

  1983cited by this paper
• SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

  1982cited by this paper
• The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin.

  1978cited by this paper
• Efficacy of somatostatin in a patient with carcinoid syndrome.

  1978cited by this paper
• Letter: HL-A antigens in myasthenia gravis.

  1974cited by this paper
• Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine.

  1970cited by this paper

• Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2-Epigenetic Circuit.

  2026cites this paper
• How the diffuse neuroendocrine system shapes health, homeostasis, and cancer.

  2025cites this paper
• Octreotide

  2025cites this paper
• Hepatic Perfusion for Diffuse Metastatic Cancer to the Liver: Open and Percutaneous Techniques.

  2025cites this paper
• A Rare Case of Neuroendocrine Tumor Presenting as Isolated Scalp Swelling With Paroxysmal Symptoms

  2025cites this paper
• Prognosis of NETs: Has There Been Improvement over the Last 30 Years?

  2025cites this paper
• Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies

  2024cites this paper
• Management of functional neuroendocrine tumors.

  2024cites this paper
• Diagnosis and comprehensive treatment of a glucagonoma in a patient with residual intrahepatic metastases postoperatively: A case report and literature review

  2024cites this paper
• Aberrant hormone receptors regulate a wide spectrum of endocrine tumors.

  2024cites this paper
• Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE

  2024cites this paper
• From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms

  2024cites this paper
• Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients

  2024cites this paper
• The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives

  2024cites this paper
• Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors

  2023cites this paper
• Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma

  2023cites this paper
• Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: a case report

  2023cites this paper
• Bioprosthetic valve monitoring in patients with carcinoid heart disease

  2023cites this paper
• Resistance of neuroendocrine tumours to somatostatin analogs

  2023cites this paper
• A case of carcinoid syndrome probably exacerbated by hemodialysis in which prochlorperazine maleate was effective

  2023cites this paper
• Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals

  2023cites this paper
• Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care

  2023cites this paper
• The role of serotonin inhibition within the treatment of carcinoid syndrome

  2023cites this paper
• Sex differences in carcinoid syndrome: A gap to be closed

  2022cites this paper
• Medical management of gastrointestinal neuroendocrine tumors

  2022cites this paper
• Gastroenteropancreatic Neuroendocrine Tumors.

  2022cites this paper
• Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome

  2022cites this paper
• Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review

  2022cites this paper
• Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies

  2022cites this paper
• Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency

  2022cites this paper
• Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues

  2022cites this paper
• Neuroendocrine Tumors: a Relevant Clinical Update

  2022cites this paper
• A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

  2022cites this paper
• Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors

  2022cites this paper
• Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy

  2022cites this paper
• Carcinoid Crisis: History, Dogmas, and Data

  2021cites this paper
• The Landmark Series: Management of Small Bowel Neuroendocrine Tumors

  2021cites this paper
• Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues

  2021cites this paper
• Treatment personalization in gastrointestinal neuroendocrine tumors

  2021cites this paper
• Neuroendocrine tumours in patients operated for acute appendicitis: a retrospective clinical study

  2021cites this paper
• Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World

  2021cites this paper
• Hepatic Perfusion for Diffuse Metastatic Cancer to the Liver: Open and Percutaneous Techniques.

  2021cites this paper
• NETs of the Lung

  2021cites this paper
• Continuing the Odyssey in the Land of Small Tumors.

  2021cites this paper
• Hydrophilic Interaction Liquid Chromatography Coupled with Fluorescence Detection (HILIC-FL) for the Quantitation of Octreotide in Injection Forms

  2021cites this paper
• [Update on neuroendocrine tumors].

  2021cites this paper
• JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

  2021cites this paper
• Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management

  2021cites this paper
• [The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)].

  2021cites this paper
• Recent Advances in the Management of Typical and Atypical Lung Carcinoids.

  2020cites this paper
• Effects of Somatostatin Analogs on Catecholamine Biosynthesis Regulated by Corticosteroids and Bone Morphogenetic Proteins in Rat Pheochromocytoma Cells

  2020cites this paper
• Clinicopathologic Features and Survival Outcomes for Primary Renal Neuroendocrine Neoplasms.

  2020cites this paper
• Rare Liver Tumors

  2020cites this paper
• Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors

  2020cites this paper
• Gastrointestinal neuroendocrine tumors in 2020

  2020cites this paper
• Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey

  2020cites this paper
• Evaluation and Management of Liver Masses

  2020cites this paper
• Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors

  2020cites this paper
• Radioligand Theranostics in the Management of Neuroendocrine Tumors.

  2020cites this paper
• Evidence Base for the Use of PRRT.

  2020cites this paper
• Cancer of the Endocrine System

  2020cites this paper
• Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.

  2020cites this paper
• Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments

  2020cites this paper
• MEDICAL MANAGEMENT OF GEPNETS

  2020cites this paper
• Rare presentation of a symptomatic primary neuroendocrine tumour of small bowel mesentery

  2020cites this paper
• The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy.

  2020cites this paper
• CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome

  2020cites this paper
• Systemic treatment for lung carcinoids: from bench to bedside

  2019cites this paper
• Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

  2019cites this paper
• A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial

  2019cites this paper
• CMAR_A_181439 7537..7556

  2019cites this paper
• Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 Trial.

  2019cites this paper
• Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.

  2019cites this paper
• TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

  2019cites this paper
• Surgery for Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

  2019cites this paper
• Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge

  2019cites this paper
• Octreotide , 40 years later

  2019cites this paper
• A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial

  2019cites this paper
• Management of Small Bowel Neuroendocrine Tumors

  2019cites this paper
• ANNIVERSARY REVIEW: Octreotide, 40 years later.

  2019cites this paper
• Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors

  2019cites this paper
• Treatment of Gastroenteropancreatic Neuroendocrine Tumors.

  2019cites this paper
• Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan

  2019cites this paper
• Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).

  2019cites this paper
• Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances

  2019cites this paper
• Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors

  2018cites this paper
• Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

  2018cites this paper
• The human somatostatin receptor type 2 as an imaging and suicide reporter gene for pluripotent stem cell-derived therapy of myocardial infarction

  2018cites this paper
• Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.

  2018cites this paper
• Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives

  2018cites this paper
• Gastroenteropancreatic Neuroendocrine Tumors

  2018cites this paper
• APENDİKS’İN KARSİNOİD TÜMÖRÜ: 3981 APENDEKTOMİ VAKASININ DEĞERLENDİRİLMESİ Carcinoid Tumor Of Appendix: Evaluatıon of 3981 Appendectomy Cases

  2018cites this paper
• New Treatments for the Carcinoid Syndrome.

  2018cites this paper
• Carcinoid syndrome: update on the pathophysiology and treatment

  2018cites this paper
• The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018.

  2018cites this paper
• S2k-Leitlinie Neuroendokrine Tumore

  2018cites this paper
• Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.

  2018cites this paper
• Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.

  2017cites this paper